Physician profile
Ian M Lonergan
NPI 1174795744
$364,388.47
in general payments reported to CMS, 2019-2025
13 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $3,941 · 2021: $9,625 · 2022: $71K · 2023: $78K · 2024: $88K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $280K · Food and Beverage: $86.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $279,937.50 |
| Food and Beverage | $86.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $279,937.50 | 2023-2025 | |
| Csl Behring | $84,125.00 | 2020-2022 | |
| Smith+Nephew, INC. | $78.18 | 2019-2022 | |
| Convatec INC. | $40.27 | 2020-2022 | |
| Avanos Medical | $38.20 | 2019 | |
| Organogenesis INC. | $35.20 | 2019-2020 | |
| Abbvie INC. | $30.55 | 2022-2023 | |
| Integra Lifesciences Corporation | $24.19 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Allergan, INC. | $21.87 | 2019 | |
| Urgo Medical North America, LLC | $18.33 | 2024 | Urgoclean Ag |
| Galderma Laboratories, L.P. | $14.18 | 2023 | |
| Mimedx Group, INC. | $13.99 | 2024 | |
| Medtronic Vascular, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Lonergan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.